Despite Sirio Pharma's lower returns, reinvestment rise and ...

Despite Sirio Pharma's lower returns, reinvestment rise and higher sales are hopeful. But the persistent drop in ROCE and 58% stock slide over three years imply a need for thorough inquiry into more business basics before deciding to invest.